Oncotarget

Research Papers:

Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models

Steven A. Greenberg _, Sek Won Kong, Evan Thompson and Stefano V. Gulla

PDF  |  Full Text  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2019; 10:1399-1406. https://doi.org/10.18632/oncotarget.26659

Metrics: PDF 1436 views  |   Full Text 1996 views  |   ?  


Abstract

Steven A. Greenberg1,2, Sek Won Kong2,3, Evan Thompson4 and Stefano V. Gulla4

1Department of Neurology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA

2Computational Health Informatics Program, Boston Children’s Hospital, Boston, MA, USA

3Department of Pediatrics, Harvard Medical School, Boston, MA, USA

4Abcuro, Inc., Newton, MA, USA

Correspondence to:

Steven A. Greenberg, email: sagreenberg@bwh.harvard.edu

Keywords: immune checkpoint receptor; immunotherapy; KLRG1; co-inhibitory receptor; murine cancer models

Received: December 12, 2018    Accepted: January 21, 2019    Published: February 15, 2019

ABSTRACT

Background: KLRG1 is a lymphocyte co-inhibitory, or immune checkpoint, receptor expressed predominantly on late-differentiated effector and effector memory CD8+ T and NK cells. Targeting of KLRG1 neutralization in murine cancer models has not previously been reported.

Methods: We studied KLRG1 expression in human blood and tumor samples from available genomic datasets. Anti-KLRG1 neutralizing antibody was studied in the murine 4T1 breast cancer as monotherapy, and in the MC38 colon cancer and B16F10 melanoma models as combination therapy with anti-PD-1 antibody.

Results: In human blood and tumor samples, KLRG1 expression is aligned with cytotoxic T and NK cell differentiation, and upregulated in human tumor samples after a variety of therapies, potentially contributing to adaptive resistance. In in vivo murine models, anti-KLRG1 antibody monotherapy in the 4T1 breast cancer model reduced lung metastases (decreased lung weights p=0.04; decreased nodule count p=0.002), while anti-KLRG1 + anti-PD-1 combination therapy in the MC38 colon cancer and B16F10 melanoma models produced synergistic benefit greater than anti-PD-1 alone for tumor volume (MC38 p=0.01; B16F10 p=0.007) and survival (MC38 p=0.02; B16F10 p=0.002).

Conclusions: These studies provide the first evidence that inhibition of the KLRG1 pathway enhances immune control of cancer in murine models, and provide target validation for KLRG1 targeting of human cancer. The mechanism of efficacy of KLRG1 blockade in murine models remains to be determined.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26659